1. Home
  2. HLP vs TRAW Comparison

HLP vs TRAW Comparison

Compare HLP & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLP
  • TRAW
  • Stock Information
  • Founded
  • HLP 2021
  • TRAW 1998
  • Country
  • HLP China
  • TRAW United States
  • Employees
  • HLP 163
  • TRAW N/A
  • Industry
  • HLP Industrial Machinery/Components
  • TRAW
  • Sector
  • HLP Industrials
  • TRAW
  • Exchange
  • HLP Nasdaq
  • TRAW NYSE
  • Market Cap
  • HLP 107.3M
  • TRAW 15.0M
  • IPO Year
  • HLP 2023
  • TRAW 2013
  • Fundamental
  • Price
  • HLP $1.46
  • TRAW $5.21
  • Analyst Decision
  • HLP
  • TRAW
  • Analyst Count
  • HLP 0
  • TRAW 0
  • Target Price
  • HLP N/A
  • TRAW N/A
  • AVG Volume (30 Days)
  • HLP 70.8K
  • TRAW 7.1K
  • Earning Date
  • HLP 12-31-2024
  • TRAW 11-14-2024
  • Dividend Yield
  • HLP N/A
  • TRAW N/A
  • EPS Growth
  • HLP N/A
  • TRAW N/A
  • EPS
  • HLP N/A
  • TRAW N/A
  • Revenue
  • HLP $14,045,084.00
  • TRAW $226,000.00
  • Revenue This Year
  • HLP N/A
  • TRAW $3.81
  • Revenue Next Year
  • HLP N/A
  • TRAW N/A
  • P/E Ratio
  • HLP N/A
  • TRAW N/A
  • Revenue Growth
  • HLP N/A
  • TRAW N/A
  • 52 Week Low
  • HLP $0.99
  • TRAW $4.06
  • 52 Week High
  • HLP $3.50
  • TRAW $27.50
  • Technical
  • Relative Strength Index (RSI)
  • HLP 57.59
  • TRAW 54.54
  • Support Level
  • HLP $1.31
  • TRAW $4.62
  • Resistance Level
  • HLP $1.59
  • TRAW $5.19
  • Average True Range (ATR)
  • HLP 0.15
  • TRAW 0.31
  • MACD
  • HLP 0.01
  • TRAW 0.04
  • Stochastic Oscillator
  • HLP 42.76
  • TRAW 70.71

About HLP Hongli Group Inc.

Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.

About TRAW TRAWS PHARMA INC

Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.

Share on Social Networks: